• Trifluoperazine 2HCl: D2 Research Guide

  2026-08-14

  Trifluoperazine 2HCl is a potent dopamine D2 receptor inhibitor for controlled studies of dopamine receptor signaling and dopaminergic pathway modulation. The product dossier reports a 1.1 nM IC50, high solvent solubility, and −20 °C storage guidance, while emphasizing fresh preparation of experimental stocks.

• Allosteric PDK4 Inhibitors for Metabolic Disease

  2026-08-13

  The reference study describes a structure-guided anthraquinone optimization campaign that produced novel allosteric pyruvate dehydrogenase kinase 4 inhibitors. Compound 8c combined nanomolar biochemical activity with favorable metabolic and pharmacokinetic observations and improved glucose tolerance and allergic responses in mouse models, while also showing anticancer activity in cellular experiments.

• Tacrolimus (FK506) Workflow for T-Cell Assays

  2026-08-13

  Build reproducible Tacrolimus assays around calcineurin–NFAT biology, controlled solvent exposure, and orthogonal cytokine readouts. This practical workflow separates FK506 effects from cyclosporine-specific biology while supporting transplantation immunology research, autoimmune disease models, and broader immune response suppression studies.

• Neuromedin S (rat): GPCR Assay Guide

  2026-08-12

  Neuromedin S (rat) provides a defined endogenous peptide agonist input for laboratory studies of neuromedin U receptor signaling and related GPCR/G protein signaling. It is intended for controlled research workflows, not diagnostic, therapeutic, or medical use, and assay-specific potency and response conditions must be established locally.

• Sex-Dependent Immune Effects of SAG in Demyelination

  2026-08-12

  The reference study shows that SAG supports myelin regeneration but modulates peripheral immunity differently in male and female demyelination models. Its most important implication is that sex-specific immune effects, particularly involving innate and T-cell responses, can determine whether Hedgehog and androgen pathway activation cooperate therapeutically.

• Otilonium Bromide: Assay Design Beyond Receptor Blockade

  2026-08-11

  Otilonium Bromide is an antimuscarinic agent for dissecting cholinergic signaling, smooth muscle physiology, and receptor-linked phenotypes. This guide goes beyond compound handling to show how pharmacological controls, orthogonal readouts, and structure-based evidence improve assay interpretation.

• TMRE mitochondrial Membrane Potential Assay Kit

  2026-08-10

  This scenario-based guide explains how SKU K2233 supports quantitative mitochondrial depolarization measurement when conventional viability assays produce ambiguous results. It covers assay principle, sample compatibility, workflow controls, interpretation limits, and practical vendor-selection criteria for biomedical laboratories.

• CK2α–VP2 Interaction in CIAV Replication

  2026-08-09

  A 2026 Journal of Virology study identifies host CK2α as an essential cellular factor for chicken infectious anemia virus replication. The work links CK2α to VP2 stabilization through a defined VP2 Ser182/Asp183 interaction and shows that disrupting this axis reduces viral replication and disease-associated tissue injury.

• Catalpol, TrkB, and Neuroinflammation in SAE

  2026-08-08

  A 2024 Journal of Ethnopharmacology study links Catalpol to recovery from LPS-induced cognitive impairment through coordinated suppression of NF-κB-regulated neuroinflammation and enhancement of TrkB–BDNF signaling. Its combination of behavioral, histological, pharmacokinetic, cellular, and target-engagement analyses provides a useful framework for neuroprotection research while leaving important questions about clinical and polymicrobial sepsis relevance.

• 740 Y-P: PI3K Activator Workflow Guide

  2026-08-07

  740 Y-P is a cell-permeable PI 3-kinase activator for controlled biochemical and cellular studies of PI3K/AKT signaling, including vesicular trafficking, neuronal cell survival, and cancer research. This guide uses product-dossier conditions as starting points and limits recommendations to in vitro workflows; the dossier does not establish animal, clinical, or ethanol-based applications.

• Necrostatin 2 (Nec-2): Precision Necroptosis Inhibition Work

  2026-08-07

  Necrostatin 2 (Nec-2) empowers researchers to precisely dissect necroptosis and RIPK2-driven cell death, particularly in ischemic stroke and apoptosis-resistant models. This guide delivers optimized protocols, troubleshooting strategies, and practical integration of membrane remodeling insights for translational and mechanistic studies.

• Plant Cell Lysis Buffer for WB and IP: Elevating Protein Int

  2026-08-06

  Discover how Plant Cell Lysis Buffer for WB and IP optimizes Western blotting sample preparation, preserves native protein interactions, and enables precise protein studies in plant systems. This article offers a unique, protocol-focused analysis grounded in recent advances in protein ubiquitination and degradation.

• L-NAME Hydrochloride: Mechanistic Precision in Translational

  2026-08-06

  Explore how L-NAME Hydrochloride (NG-nitro-L-arginine methyl ester) transforms vascular and inflammation research, bridging mechanistic insight with strategic translational guidance. Discover best practices, evidence-driven protocols, and the evolving landscape of nitric oxide modulation in cardiovascular and renal disease models.

• HOBt (1-Hydroxybenzotriazole): Elevating Amide Bond Formatio

  2026-08-05

  HOBt (1-Hydroxybenzotriazole) is the gold-standard additive for minimizing epimerization and maximizing yield during peptide synthesis and amide bond formation. Discover how APExBIO’s high-purity HOBt enables advanced workflows for complex bioactive molecule synthesis, including glucagon receptor antagonists and antibiotic derivatives.

• Ziprasidone Augmentation of Escitalopram in Anxious Depressi

  2026-08-05

  This article analyzes a post-hoc study examining the efficacy of ziprasidone augmentation in patients with major depressive disorder (MDD) who exhibit anxious versus nonanxious features while on escitalopram. The findings clarify that while ziprasidone is equally effective for depressive symptoms across groups, its anxiolytic benefits are limited, informing the design of future antidepressant and anxiolytic research models.

451 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page